Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1
USD
|
+1.20%
|
|
-9.09%
|
-9.91%
|
Fiscal Period: Marzo |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
114.2
|
118.5
|
53.5
|
68.61
|
32.73
|
19.08
|
Enterprise Value (EV)
1 |
70.44
|
82.06
|
26.15
|
31.24
|
6.241
|
4.883
|
P/E ratio
|
-3.17
x
|
-4.3
x
|
-2.84
x
|
-3.95
x
|
-2.86
x
|
-1.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
24.8
x
|
38.3
x
|
24.4
x
|
-
|
21.8
x
|
51.6
x
|
EV / Revenue
|
15.3
x
|
26.5
x
|
11.9
x
|
-
|
4.16
x
|
13.2
x
|
EV / EBITDA
|
-2.07
x
|
-3.12
x
|
-1.69
x
|
-2.24
x
|
-0.55
x
|
-0.28
x
|
EV / FCF
|
-4.34
x
|
-7.5
x
|
-4.16
x
|
-6.61
x
|
-1.29
x
|
-0.73
x
|
FCF Yield
|
-23%
|
-13.3%
|
-24%
|
-15.1%
|
-77.3%
|
-138%
|
Price to Book
|
2.57
x
|
3.39
x
|
2.01
x
|
2.13
x
|
1.08
x
|
1.25
x
|
Nbr of stocks (in thousands)
|
5,542
|
5,975
|
6,525
|
7,117
|
8,706
|
8,715
|
Reference price
2 |
20.60
|
19.84
|
8.200
|
9.640
|
3.760
|
2.190
|
Announcement Date
|
5/31/18
|
6/3/19
|
5/28/20
|
6/15/21
|
6/10/22
|
7/14/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
4.603
|
3.091
|
2.196
|
-
|
1.5
|
0.37
|
EBITDA
1 |
-34
|
-26.29
|
-15.51
|
-13.98
|
-11.34
|
-17.44
|
EBIT
1 |
-35.27
|
-27.27
|
-15.75
|
-14.02
|
-11.48
|
-17.73
|
Operating Margin
|
-766.26%
|
-882.37%
|
-717.12%
|
-
|
-765.27%
|
-4,792.16%
|
Earnings before Tax (EBT)
1 |
-34.8
|
-26.63
|
-18.71
|
-16.82
|
-11.45
|
-17.26
|
Net income
1 |
-34.8
|
-26.64
|
-18.71
|
-16.83
|
-11.45
|
-17.26
|
Net margin
|
-756.09%
|
-861.7%
|
-852%
|
-
|
-763.2%
|
-4,664.59%
|
EPS
2 |
-6.490
|
-4.617
|
-2.888
|
-2.438
|
-1.315
|
-1.981
|
Free Cash Flow
1 |
-16.22
|
-10.94
|
-6.284
|
-4.73
|
-4.826
|
-6.716
|
FCF margin
|
-352.3%
|
-353.81%
|
-286.18%
|
-
|
-321.76%
|
-1,815.1%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/31/18
|
6/3/19
|
5/28/20
|
6/15/21
|
6/10/22
|
7/14/23
|
Fiscal Period: March |
2024 Q1
|
2024 Q2
|
2024 Q3
|
---|
Net sales
1 |
-
|
-
|
0.005
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
-4.115
|
-3.68
|
Operating Margin
|
-
|
-
|
-73,600%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
Net income
1 |
-4.028
|
-3.994
|
-3.604
|
Net margin
|
-
|
-
|
-72,080%
|
EPS
2 |
-0.4600
|
-0.4600
|
-0.4000
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
8/10/23
|
11/9/23
|
2/8/24
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
43.7
|
36.5
|
27.4
|
37.4
|
26.5
|
14.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-16.2
|
-10.9
|
-6.28
|
-4.73
|
-4.83
|
-6.72
|
ROE (net income / shareholders' equity)
|
-65.1%
|
-65.9%
|
-59.5%
|
-51.1%
|
-33%
|
-75.8%
|
ROA (Net income/ Total Assets)
|
-37%
|
-37.7%
|
-28.5%
|
-25.6%
|
-19.6%
|
-41.3%
|
Assets
1 |
93.94
|
70.66
|
65.64
|
65.64
|
58.41
|
41.75
|
Book Value Per Share
2 |
8.030
|
5.850
|
4.080
|
4.520
|
3.470
|
1.760
|
Cash Flow per Share
2 |
7.880
|
5.880
|
4.190
|
4.310
|
3.290
|
1.760
|
Capex
1 |
0.23
|
0.08
|
-
|
0.41
|
0.41
|
0.4
|
Capex / Sales
|
4.91%
|
2.56%
|
-
|
-
|
27.27%
|
107.03%
|
Announcement Date
|
5/31/18
|
6/3/19
|
5/28/20
|
6/15/21
|
6/10/22
|
7/14/23
|
|
1st Jan change
|
Capi.
|
---|
| -9.91% | 11.39M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|